Artal Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Artal Group’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-157,000	Closed	-$1.04M	–	139
2022 Q3	$1.04M	Sell	157,000 -843,000	-84%	-$5.19M	0.04%	113
2022 Q2	$4.84M	Hold	1,000,000	–	–	0.26%	60
2022 Q1	$9.35M	Hold	1,000,000	–	–	0.39%	49
2021 Q4	$11.9M	Hold	1,000,000	–	–	0.32%	65
2021 Q3	$11.4M	Hold	1,000,000	–	–	0.25%	76
2021 Q2	$17.9M	Buy	1,000,000 +200,000	+25%	+$3.22M	0.36%	59
2021 Q1	$12.4M	Buy	800,000 +500,000	+167%	+$7.23M	0.22%	90
2020 Q4	$3.66M	Buy	+300,000	New	+$4.18M	0.08%	114
2019 Q1	–	Sell	-125,000	Closed	-$1.44M	–	119
2018 Q4	$1.44M	Hold	125,000	–	–	0.05%	99
2018 Q3	$5M	Hold	125,000	–	–	0.13%	76
2018 Q2	$3.54M	Hold	125,000	–	–	0.08%	82
2018 Q1	$1.91M	Buy	125,000 +75,000	+150%	+$1.79M	0.02%	93
2017 Q4	$1.63M	Buy	+50,000	New	+$1.35M	0.02%	100

Other funds holding MRNS

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Artal Group's MRNS Position: Q4 2022 in Review

Artal Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2022, closing a stake of 157,000 shares — an estimated $1.04M sold.

Artal Group first reported a position in MRNS in Q4 2017 and held it in 13 quarters. The position peaked at $17.9M in Q2 2021. 74 funds tracked by Wall St. Rank hold MRNS as of Q4 2022.

Artal Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
Artal Group sold 157,000 Marinus Pharmaceuticals, Inc shares in Q4 2022, an estimated $1.04M.
Artal Group first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 13 quarters.
Artal Group's Marinus Pharmaceuticals, Inc position peaked at $17.9M in Q2 2021.
74 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2022.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.